Global Cancer Tumor Profiling Market

Cancer Tumor Profiling Market Size, Share, Growth Analysis, By Cancer type (Breast Cancer, Lung Cancer), By Biomarker type (Genomic Biomarker, Protein Biomarker), By Technology, By Technique, By Application, By Region - Industry Forecast 2026-2033

Report ID: SQMIG35G2114 | Region: Global | Published Date: December, 2025
Pages: 219 | Tables: 62 | Figures: 78

Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Cancer Tumor Profiling Market size was valued at USD 13.44 Billion in 2024 and is poised to grow from USD 14.93 Billion in 2025 to USD 34.66 Billion by 2033, growing at a CAGR of 11.1% during the forecast period (2026–2033). 

    The market for cancer/tumor profiling products is growing, with new companies coming up with new ways to make money. MDNA Life Sciences Inc. launched its liquid biopsy Prostate Mitomic Test in May 2017 in the United States. Together with Helomics Corp., this test is designed to help doctors diagnose prostate cancer. The test uses the unique genetic characteristics of mitochondrial DNA, and it is exclusively available at Helomics' clinical laboratories. In April 2017, Helomics Corporation also launched its Dynamic Clinical Health Insight Platform (D-CHIP), which can be used to study the detailed information related to cancer patients' genomes, proteins, DNA, and RNA in order to identify more-effective biomarkers for pharmaceutical and diagnostic companies. 'Illumina, Inc. (USA) ', 'QIAGEN N.V. (Netherlands) ', 'NeoGenomics, Inc. (USA) ', 'Thermo Fisher Scientific (USA) ', 'Roche Diagnostics (Switzerland) ', 'Guardant Health, Inc. (USA) ', 'Foundation Medicine, Inc. (USA) ', 'Sysmex Corporation (Japan) ', 'Becton, Dickinson and Company (BD) (USA) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'Merck & Co., Inc. (USA) ', 'Pfizer Inc. (USA) ', 'Novartis AG (Switzerland) ', 'AstraZeneca (UK) ', 'Bristol-Myers Squibb Company (USA) ', 'Johnson & Johnson (USA) ', 'Danaher Corporation (USA) ', 'Abbott Laboratories (USA) '

    Increase in cancer incidences is one of the major contributors to market growth in the complete cancer/tumor profiling market. the increasing burden of cancer can be attributed to various factors, Cancer is a complex and widespread disease, caused by a variety of factors. Population growth and aging, as well as the changing prevalence of certain causes of cancer, are all contributors to its prevalence.

    The trends in the cancer/tumor profiling market is the Integration of omics data and advances in liquid biopsy tests is expected to grow at the highest CAGR during the forecast period. Personalized medicine is a growing field of healthcare research that is changing the way diseases are identified, classified, and treated. It has now become mainstream clinical practice, and is being used to treat many different diseases. The advances in cancer care are particularly apparent in the area of oncology.

    North America is estimated to account for the largest share in terms of revenue owing to the presence of major players and rapid advances in technology. The high prevalence of cancer and the increasing research in oncology will lead to increased market growth in the treatment of cancer. The large share of the regional market for these diagnostic kits is due in large part to the quick uptake of advanced technologies by the firms manufacturing these kits.

    Related Reports

    Cancer Diagnostics Market
    Buy Now GET FREE SAMPLE
    Cancer Biomarkers Market
    Buy Now GET FREE SAMPLE
    Next Generation Cancer Diagnostics Market
    Buy Now GET FREE SAMPLE
    Clinical Oncology Next Generation Sequencing Market
    Buy Now GET FREE SAMPLE
    Cancer Therapeutics Market
    Buy Now GET FREE SAMPLE
    Companion Diagnostics for Oncology Market
    Buy Now GET FREE SAMPLE
    Cancer Biological Therapy Market
    Buy Now GET FREE SAMPLE
    Breast Cancer Diagnostics Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Cancer Tumor Profiling Market

    Report ID: SQMIG35G2114

    $5,300
    BUY NOW GET FREE SAMPLE